Elevance Health, Inc. (NYSE:ELV) Given Consensus Rating of “Moderate Buy” by Brokerages

Elevance Health, Inc. (NYSE:ELV) has earned an average recommendation of “Moderate Buy” from the twenty-three brokerages that are covering the company, Marketbeat reports. Nine investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $416.1053.

Several research firms have recently commented on ELV. Weiss Ratings raised Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, May 18th. Sanford C. Bernstein increased their price objective on Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a research report on Friday, April 24th. Robert W. Baird raised their target price on Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a report on Thursday, April 23rd. Morgan Stanley boosted their target price on shares of Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a research report on Thursday, June 4th. Finally, Mizuho upped their price target on shares of Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a research note on Monday, June 8th.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Nephron Research issued forecasts implying continued earnings growth for Elevance Health, including FY2027 EPS of $28.95, which may reinforce confidence in the company’s long-term profitability. Elevance Health stock and earnings report
• Positive Sentiment: Analyst commentary highlighted Carelon as a potential growth engine for ELV, with the unit expected to support revenues, care efficiency, and future earnings growth. Carelon growth article
• Neutral Sentiment: Elevance Health’s FY2026 EPS estimate from Nephron Research came in at $25.73, a bit below the current consensus of $26.92, which is not a major negative but may temper some near-term enthusiasm.
• Neutral Sentiment: Additional articles focused on what to expect from Q2 2026 earnings and investor reaction to a platform deal, but they did not provide a clear new fundamental surprise for the stock. Q2 2026 earnings expectations Investor reaction article

Elevance Health Stock Up 1.9%

Shares of NYSE:ELV opened at $394.86 on Friday. Elevance Health has a fifty-two week low of $273.71 and a fifty-two week high of $426.98. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. The firm’s 50-day simple moving average is $383.03 and its 200-day simple moving average is $349.01. The company has a market cap of $85.75 billion, a price-to-earnings ratio of 16.80, a PEG ratio of 2.24 and a beta of 0.67.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. During the same quarter last year, the firm earned $11.97 earnings per share. The firm’s revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities research analysts predict that Elevance Health will post 26.86 earnings per share for the current year.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Investors of record on Wednesday, June 10th were issued a dividend of $1.72 per share. The ex-dividend date of this dividend was Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. Elevance Health’s payout ratio is currently 29.26%.

Insider Transactions at Elevance Health

In other news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the sale, the director directly owned 10,734 shares in the company, valued at approximately $4,312,599.18. This trade represents a 1.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Elevance Health

Institutional investors and hedge funds have recently modified their holdings of the company. Sapient Capital LLC grew its holdings in Elevance Health by 1.2% in the first quarter. Sapient Capital LLC now owns 2,612 shares of the company’s stock valued at $765,000 after purchasing an additional 31 shares during the last quarter. Western Wealth Management LLC raised its stake in shares of Elevance Health by 205.9% during the 1st quarter. Western Wealth Management LLC now owns 3,738 shares of the company’s stock worth $1,094,000 after buying an additional 2,516 shares during the last quarter. DV Trading LLC boosted its position in shares of Elevance Health by 244.3% in the 1st quarter. DV Trading LLC now owns 964 shares of the company’s stock worth $282,000 after buying an additional 684 shares in the last quarter. NewEdge Advisors LLC boosted its position in shares of Elevance Health by 21.4% in the 1st quarter. NewEdge Advisors LLC now owns 18,964 shares of the company’s stock worth $5,552,000 after buying an additional 3,343 shares in the last quarter. Finally, Axiom Investment Management LLC acquired a new stake in Elevance Health in the 1st quarter valued at about $542,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.